WHEREAS, Hundreds of thousands of people in the United States
including the State of Washington depend on protein therapies derived
from human plasma, known as plasma therapies, to treat serious and
life-threatening diseases and conditions such as hemophilia, primary
immune disorder, Alpha-1 Antitrypsin deficiency (Alpha-1), Rh Negative
blood incompatibility, shock, and burns; and
WHEREAS, Assuring the continued quality and safety of plasma
therapies is a top priority of patients, public health authorities, and
the plasma collection and fractionation industry; and
WHEREAS, The plasma industry and its global trade association have
developed the quality standards of excellence assurance and leadership
and international quality plasma program standards that currently
represent the highest reasonably attainable quality and safety
standards for human source plasma used in the processing of plasma
protein therapies; and
WHEREAS, These quality standards of excellence assurance and
leadership standards include:
Strict criteria for the selection of qualified donors, including
the requirements that the donor successfully pass a minimum of two
separate health screenings and two separate validated laboratory tests
before any donation can be used;
The use of a sixty-day inventory hold and the requirement that if
new information is received indicating that a donor is no longer
qualified, previous donations from that donor held in inventory are
required to be destroyed;
The use of state-of-the-art Nucleic acid Amplification Technology
(NAT) to detect any potential presence of human immunodeficiency virus
(HIV), Hepatitis B virus (HBV), and Hepatitis C virus (HCV) and any
potential presence at critical levels of parvovirus B19; and
The requirement that plasma used to produce plasma therapies be
collected at centers that adhere to, and are judged by, specific strict
viral marker standards; and
WHEREAS, These quality standards of excellence assurance and
leadership and international quality plasma program standards provide
an extra margin of safety beyond federal and state regulatory
requirements for the collecting, processing, and testing of human
plasma; and
WHEREAS, These quality standards of excellence assurance and
leadership and international quality plasma program standards have
helped drive the adoption of enhanced and consistent safety standards
for plasma collection and processing; and
WHEREAS, It is important to further increase public awareness of
the value of donating blood and plasma, as well as an appreciation of
the safety of plasma therapies and the processes by which that safety
is assured;
NOW, THEREFORE, BE IT RESOLVED, By the House of Representatives of
the State of Washington, That the quality standards of excellence
assurance and leadership and international quality plasma program
certification programs are important ways to ensure that only the
highest quality plasma is collected and used for processing of plasma-derived therapeutic proteins; and
BE IT FURTHER RESOLVED, That entities that collect plasma recovered
from whole blood should implement a quality and safety standards
certification program comparable to quality standards of excellence
assurance and leadership and international quality plasma program; and
BE IT FURTHER RESOLVED, That health care professionals and health
plans that purchase or provide plasma proteins for patient care should
use therapeutics that employ rigorous quality systems, as exemplified
by the quality standards of excellence assurance and leadership and
international quality plasma program certification programs, which are
aimed at assuring the highest quality and safety of plasma donations
from which plasma therapies are derived; and
BE IT FURTHER RESOLVED, That all facilities that collect blood and
plasma for fractionation into plasma therapeutic proteins that are
certified under the international quality plasma program, and
processors that fractionate source plasma that are certified under the
quality standards of excellence assurance and leadership program be
commended for receiving such certification.